chr16-1220557-G-C
Variant summary
Our verdict is Benign. The variant received -11 ACMG points: 0P and 11B. BP4_ModerateBP6BS1BS2
The NM_021098.3(CACNA1H):c.6625G>C(p.Ala2209Pro) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000308 in 1,531,080 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_021098.3 missense
Scores
Clinical Significance
Conservation
Publications
- hyperaldosteronism, familial, type IVInheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
- childhood absence epilepsyInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- epilepsy, childhood absence, susceptibility to, 6Inheritance: AD Classification: LIMITED Submitted by: G2P, Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Our verdict: Benign. The variant received -11 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_021098.3. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| CACNA1H | NM_021098.3 | MANE Select | c.6625G>C | p.Ala2209Pro | missense | Exon 35 of 35 | NP_066921.2 | ||
| CACNA1H | NM_001005407.2 | c.6607G>C | p.Ala2203Pro | missense | Exon 34 of 34 | NP_001005407.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| CACNA1H | ENST00000348261.11 | TSL:1 MANE Select | c.6625G>C | p.Ala2209Pro | missense | Exon 35 of 35 | ENSP00000334198.7 | ||
| CACNA1H | ENST00000569107.6 | TSL:1 | c.6640G>C | p.Ala2214Pro | missense | Exon 34 of 34 | ENSP00000454990.2 | ||
| CACNA1H | ENST00000711493.1 | c.6610G>C | p.Ala2204Pro | missense | Exon 34 of 34 | ENSP00000518778.1 |
Frequencies
GnomAD3 genomes AF: 0.000210 AC: 32AN: 152048Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.000238 AC: 40AN: 167994 AF XY: 0.000207 show subpopulations
GnomAD4 exome AF: 0.000319 AC: 440AN: 1379032Hom.: 0 Cov.: 35 AF XY: 0.000311 AC XY: 211AN XY: 679326 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.000210 AC: 32AN: 152048Hom.: 0 Cov.: 32 AF XY: 0.000229 AC XY: 17AN XY: 74272 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Epilepsy, childhood absence, susceptibility to, 6;C4310756:Hyperaldosteronism, familial, type IV Uncertain:1
Inborn genetic diseases Uncertain:1
The c.6625G>C (p.A2209P) alteration is located in exon 35 (coding exon 34) of the CACNA1H gene. This alteration results from a G to C substitution at nucleotide position 6625, causing the alanine (A) at amino acid position 2209 to be replaced by a proline (P). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.
Idiopathic generalized epilepsy;C4310756:Hyperaldosteronism, familial, type IV Benign:1
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at